Affimed’s Post

Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://bit.ly/3A80Q8t #LCSM

Today, David E Anderson, Ph.D., VBI's CSO, presented encouraging early tumor response data from the Phase 2b study of VBI-1901 in recurrent #GBM at The World Vaccine Congress. Read more about the data here: https://bit.ly/4cKzzYA. GBM is a highly aggressive and underserved medical need with few treatment options available. Any advancement in patient care, particularly in the recurrent setting, would be critical. We look forward to progressing the Phase 2b study and to sharing additional data later this year. #WVCDC

EpicentRx CEO Dr. Tony Reid spoke with exquisite precision about the promising potential of AdAPT-001 to treat patients with refractory tumors such as advanced #sarcomas at PMWC - Precision Medicine World Conference’s #PMWC24 last week.   Our lead candidate, AdAPT-001, is an adenovirus that expresses a TGF-β “trap,” which binds to and neutralizes the ubiquitously overexpressed immunosuppressive cytokine, TGF-β. Initial data from a Phase 1/2 study demonstrated that AdAPT-001 is well-tolerated with impressive evidence of durable responses in combination with a checkpoint inhibitor that patients had already received—and failed. Learn more about the precision of AdAPT-001 here: https://bit.ly/41a3LXH

According to James Chih-Hsin Yang, MD, PhD, National Taiwan University, this study “achieved its primary objective, with manageable safety profile in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins.” Learn more: https://lnkd.in/eePezGb8

Preprint: #MultipleSclerosis Patients taking Glucagon-like Peptide-1 Receptor (#GLP1) Agonists: A Single-Institution Retrospective Cohort Study of Tolerability and #Weight Loss "We present a within-cohort analysis of MS patients on GLP-1 agonists for future neurologists to guide decision-making in the MS clinic. Our cohort in general provides reassurance for MS neurologists and patients, with no unexpected findings for patients with MS compared to the pivotal GLP-1 trials." https://lnkd.in/gg78pcMf

We are pleased to share positive preliminary results of SAT-3247 treatment in a canine model of Duchenne muscular dystrophy that was presented at the Parent Project Muscular Dystrophy 30th Annual Conference. This model represents a severe dystrophy that closely reflects disease progression observed in people with DMD. The data show that SAT-3247 treatment improved muscle repair and regeneration as well as improvements in muscle force, an indicator of muscle strength and functional capacity. Our CSO Philip Lambert said, “While preliminary, these results further build and support our understanding of the unique mechanism of action of SAT-3247. We continue to work diligently to advance this novel small molecule drug candidate into a first-in-human clinical trial this quarter.” Learn more here: https://lnkd.in/gQPacUjy #Duchenne #musculardystrophy #regenmed #regenerativemedicine

Discover the role of the wedge sign, common uses of uses of TFAST®, and more in this guide to performing lung ultrasounds for pulmonary thromboembolism: https://hubs.la/Q02BbGMl0 #Oncura #OncuraPartners #OncuraUltrasound #VetMed

Why is sample availability a significant barrier in biomarker testing, how does it affect specific indications like NSCLC? In our latest blog, precision medicine expert Dr. Helen Sadik answers frequently asked questions surrounding the key barriers that hinder seamless integration into the treatment pathway for a precision medicine therapy. Click the link below to discover 12 recommendations to drive your launch strategy to success: https://lnkd.in/e79YTNrJ #BetterTestingBetterTreatment #PrecisionMedicine

Perioperative #IO based therapy has shown benefits in patients with resectable stages II-III non-metastatic #NSCLC, with results from CheckMate -77T recently being published in the New England Journal of Medicine. At #ASCO24 Dr Tina Cascone will present an exploratory analysis of this regimen in patients with resectable stage III N2 and non-N2 NSCLC, a subgroup with high unmet need. Discover why we are committed to improving outcomes for all patients living with #lungcancer. https://bit.ly/3VoHCng

Nizubaglustat is a novel, orally available, brain penetrant, potent, and selective dual inhibitor of ceramide glucosyltranferase and non-lysosomal neutral glucosylceramidase, which has been discovered by Hermen Overkleeft, Hans Aerts and me at Leiden University and currently under development by Azafaros. Today Azafaros announced completion of Phase 2 clinical study RAINBOW in patients, who are affected by GM2 gangliosidosis or Niemann-Pick disease type C, in order to identify the target dosage for nizubaglustat in Phase 3 pivotal studies. https://lnkd.in/ez7iuW-K